Anti-Microbial Savior BioteQ Co Ltd

Anti-Microbial Savior BioteQ Co Ltd exhibits a highly liquid capital structure, with a current ratio of 47.84, indicating strong short-term liquidity. The company's price-to-book ratio of 4.23 and price-to-tangible-book ratio of 4.23 suggest a premium valuation relative to its book value. However, the enterprise value to EBITDA ratio is negative at -22.54, reflecting the company's current unprofitability. The company's profitability metrics are weak, with a return on equity of -18.33% and a return on assets of -17.99%, both significantly below the industry median for biotechnology firms. These figures indicate that the company is not generating returns for shareholders or efficiently utilizing its assets. Geographically, the company's revenue is concentrated in Taiwan, with no disclosed international revenue segments. The company's product portfolio is centered on three key drugs, with no material diversification across therapeutic areas or geographic markets. The company's revenue growth is constrained, with no disclosed revenue growth in the most recent period. The operating income and net income are both negative, with operating losses of TWD 95.99 million and net losses of TWD 93.60 million, respectively. The company's free cash flow is negative at TWD 89.75 million, indicating a lack of cash generation. The company's risk profile is moderate, with a low dilution risk and a medium liquidity risk. The company has no long-term debt, and its total liabilities are minimal at TWD 9.92 million. However, the company's negative operating cash flow and free cash flow raise concerns about its ability to sustain operations without external financing. Recent filings and transcripts indicate that the company is focused on advancing its drug pipeline, particularly the development of SIPSIPT and FORMOSA-1117. No material regulatory or legal events have been disclosed in the most recent filings.